MDCK-MRP2 - Dkfz

Forschungsschwerpunkt E
Innovative Krebsdiagnostik und -therapie
[15] Martin-Villalba, A., Hahne, M., Kleber, S., Vogel, J.,
Schenkel, J. and Krammer, P.H.: “Therapeutic neutralization of
CD95-ligand and TNF attenuates brain damage in stroke”, Cell
Death Differ. 8, 679-686 (2001).
[16] Schenkel, J: “Versuchstierkunde”, Fernstudium Biologie,
Spektrum Akademischer Verlag, Heidelberg 2001, ISBN
949998715.
[17] Becker, L., von Wegerer, J., Schenkel, J., Zeilhofer, H.U.,
Swandulla, D., and Weiher, H.: “Disease specific human GlyR alpha1
subunit causes Hyperekplexia phenotype and impaired glycine-
and GABA-A receptor transmission in transgenic mice”; J.
Neurosci. 22(7), 2505-2512 (2002).
[18] Zhang, W., Thomas, D., Karle, C.A., Kathöfer, S., Schenkel,
J., Kreye, V.A.W., Ficker, E., Wible, B.A., and Kiehn, J.: “Protein
kinase A-mediated phosphorylation of HERG potassium channels
in a human cell line”, Chin. Med. J. (Engl) 115 (5), 668-676
(2002).
[19] Winter, C., Weiss, C., Martin-Villalba, A., Zimmermann, M.
and Schenkel, J.: “JunB and Bcl-2 overexpression results in protection
against cell death of nigral neurons”, Brain Res. Mol. Brain
Res. 104 (2), 194-202 (2002).
[20] Hartenstein, B., Teurich, S., Hess, J., Schenkel, J., Schorpp-
Kistner, M. and Angel, P.: “Th2 Cell Specific Cytokine Expression
and Allergen-Induced Airway Inflammation depend on JunB”,
EMBO J., 21 (23), 6321-6329 (2002).
[21] Kabsch, K., Mossadegh, N., Kohl, A., *Komposch, G.,
Schenkel, J., Alonso; A., and Tomakidi, P.: “The HPV-16 E5 protein
inhibits TRAIL- and FasL-mediated apoptosis in human
keratinocyte raft cultures”. Intervirology, 47 (1), 48-56 (2004).
[22] Schenkel, J.: “Activation of the c-Jun Transcription Factor
following Neurodegeneration in vivo”, Neuroscience Lett.361, 36-
39 (2004).
Klinische Kooperationseinheit E160
Molekulare Hämatologie/Onkologie
DKFZ 2004: Wissenschaftlicher Ergebnisbericht 2002 - 2003
359